Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Other Non Operating Income (2018 - 2026)

Immunovant filings provide 8 years of Other Non Operating Income readings, the most recent being -$54000.0 for Q4 2025.

  • Quarterly Other Non Operating Income rose 95.71% to -$54000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 176.98% year-over-year, with the annual reading at $471000.0 for FY2025, 146.73% up from the prior year.
  • Other Non Operating Income hit -$54000.0 in Q4 2025 for Immunovant, down from $250000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.2 million in Q2 2025 and bottomed at -$2.6 million in Q1 2024.
  • Average Other Non Operating Income over 5 years is $24500.0, with a median of $147000.0 recorded in 2022.
  • The largest annual shift saw Other Non Operating Income plummeted 1441.23% in 2022 before it skyrocketed 4139.29% in 2025.
  • Immunovant's Other Non Operating Income stood at -$114000.0 in 2021, then plummeted by 1441.23% to -$1.8 million in 2022, then surged by 162.27% to $1.1 million in 2023, then tumbled by 214.99% to -$1.3 million in 2024, then surged by 95.71% to -$54000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Other Non Operating Income are -$54000.0 (Q4 2025), $250000.0 (Q3 2025), and $1.2 million (Q2 2025).